Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Denali TherapeuticsDNLI +5.63%33 Cyclically Adjusted PS Ratio is 16.26 as of Aug. 20, 2026, which is 5% above its 10-year median of 15.42. GuruFocus rates DNLI with a GF Score™ of 33/100. The stock has 6 warning signs investors should review. Among 532 Biotechnology companies, Denali Therapeutics ranks worse than 73.31% on this metric.
The historical rank and industry rank for Denali Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
DNLI'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 14.57 Med: 15.42 Max: 16.35
Current: 15.36
During the past years, Denali Therapeutics's highest Cyclically Adjusted PS Ratio was 16.35. The lowest was 14.57. And the median was 15.42.
DNLI's Cyclically Adjusted PS Ratio is ranked worse than 73.31% of 532
companies
in the Biotechnology industry
Industry Median: 5.745
vs DNLI: 15.36
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Denali Therapeutics's adjusted revenue per share data for the three months ended in Jun. 2026 was $0.019. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.58 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Denali Therapeutics (NAS:DNLI) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Denali Therapeutics Cyclically Adjusted PS Ratio Related Terms
Denali Therapeutics Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Denali Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denali Therapeutics Cyclically Adjusted PS Ratio Chart
DNLI vs RCUS, ALMS, ELVN: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Denali Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Denali Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Denali Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Denali Therapeutics's Cyclically Adjusted PS Ratio falls into.
Denali Therapeutics Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Denali Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 16.26 mean?
Denali Therapeutics (DNLI) has a Cyclically Adjusted PS Ratio of 16.26 as of Aug. 20, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Denali Therapeutics and its competitors. This is near median its historical median of 15.42. Over the past decade, Denali Therapeutics' Cyclically Adjusted PS Ratio has ranged from 14.57 to 16.35. According to the industry distribution chart, Denali Therapeutics ranks #390 out of 532 companies in the Biotechnology industry, placing it in the top 73.3%.
Is Denali Therapeutics' Cyclically Adjusted PS Ratio too high?
Denali Therapeutics' current Cyclically Adjusted PS Ratio of 16.26 is near median its 10-year median of 15.42. Over the past 10 years, this metric has ranged from a low of 14.57 to a high of 16.35. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.75. Denali Therapeutics' value of 16.26 is 183% above this industry median. Based on the distribution chart, Denali Therapeutics ranks #390 out of 532 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Denali Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' Cyclically Adjusted PS Ratio compare to RCUS and ALMS?
According to the Biotechnology industry distribution chart, Denali Therapeutics ranks #390 out of 532 companies for Cyclically Adjusted PS Ratio. This places Denali Therapeutics in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.75. Denali Therapeutics' value of 16.26 is 183% above this benchmark. Historically, Denali Therapeutics' own Cyclically Adjusted PS Ratio has ranged from 14.57 to 16.35 over the past decade. While the company's 10-year median is 15.42 vs. the industry median of 5.75, Denali Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.75, based on 532 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Denali Therapeutics's current Cyclically Adjusted PS Ratio of 16.26 is 183% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Denali Therapeutics and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Denali Therapeutics's current Cyclically Adjusted PS Ratio is 16.26, which is near median its own 10-year median of 15.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Denali Therapeutics (DNLI) has a current Cyclically Adjusted PS Ratio of 16.26. The current Cyclically Adjusted PS Ratio is 16.26, which is near median its 10-year median of 15.42 and 183% above the Biotechnology industry median of 5.75. Denali Therapeutics' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Denali Therapeutics (DNLI), the current Cyclically Adjusted PS Ratio is 16.26 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
33GF Score
Get the complete analysis for DNLI
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNLI has been successfully added to your 
